Page 8 - OHKF_Biotech_EN
P. 8

Executive summary  its branding advantage will be leveraged to introduce Hong Kong-  the two cities, including the GBA sub-centres for drug and medical
                 style management into the Mainland to meet international
                                                                            device evaluation and inspection established by the National
                                                                            Medical Products Administration in the Shenzhen park, and the
                 standards. For the production stage, we recommend that
                                                                            subsidiaries of the National Intellectual Property Administration
                 production lines for cutting-edge products and pilot batches be
                                                                            and the Human Genetic Resources Administration of China,
                 set up in the Loop. For the product launch stage, as new drug
                 approval standards in the Mainland are increasingly in line with
                                                                            in the Loop. Second, the platform can interface with research
                 international standards, particularly with marked improvement in   Ministry of Science and Technology that we propose to be set up
                 the quality of clinical trial data, Hong Kong’s Department of Health   project funds set up by the two governments, venture capital
                 should consider adding mainland China into its designated list, so   funds, research institutes and collaboration opportunities, as well
                 that new drugs that are launched in any two places on the list will   as professional services such as intellectual property services.
                 be recognised in Hong Kong; in the long run, Hong Kong can   Finally, the platform can attract Contract Research Organisations
                 attract and train talent in drug approval and explore the   (CRO) and Contract Development and Manufacturing
                 development of an independent new drug approval mechanism.   Organisations (CDMO) to share some of their R&D procedures
                 Likewise, the Shenzhen government should seek approval from   with biomedical companies, thereby enhancing the clinical trial
                 the Health Commission of Guangdong Province to relax relevant   capabilities and quality control standards of
                 requirements and allow the use of efficacy data of drugs and   healthcare organisations.
                 medical devices, which have already been approved in Hong
                 Kong, on Shenzhen patients for further registration in the   Recommendation 4   Encouraging
                 Mainland. This will expedite the overall approval process.   knowledge transfer in tertiary institutions and
                                                                              nurturing multi-skilled talent well-versed
                   Recommendation 3   Establishing                            in biotech and business
                   a one-stop service platform in the Loop to
                   provide professional support services                    While the Regulation of Shenzhen Special Economic Zone on
                                                                            Scientific and Technological Innovation contains a number of
                 To better leverage the Loop to help Mainland enterprises expand   measures aimed at encouraging knowledge transfer, Hong Kong
                 into international markets and Hong Kong enterprises access the   has a lot to catch up on. To prevent researchers and enterprises
                 Mainland market, we recommend the joint establishment of a   from flowing one way and congregating into a particular park in the
                 one-stop service platform in the Loop by the Hong Kong-    Loop, and to more efficiently transfer world-class research outcomes
                 Shenzhen Innovation and Technology Park Limited and the Futian   into the industry, we propose the following recommendations:
                 district government to provide biotechnology transfer services.   1) the University Grants Committee of Hong Kong should establish
                 First, such a platform can liaise with the competent regulators of   an assessment framework for knowledge transfer in tertiary institutions
       6
   3   4   5   6   7   8   9   10   11   12   13